Navigation Links
Meditrina Pharmaceuticals, Inc. Announces Allowance of Patent for Treatment of Endometriosis

ANN ARBOR, Mich., Sept. 9 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca. The patent claims are directed to the use of anastrozole in combination with an estrogen and a progestin and protect Meditrina's endometriosis product MPI-676.

"The allowance of this patent to our licensor AstraZeneca is a significant step forward in the protection of our approach to treating endometriosis with our proprietary endometriosis product, MPI-676," said Thomas A. Collet, president and CEO. "This patent also extends protection for MPI-676 in the world's largest pharmaceutical market in addition to Europe, Australia, China, Indonesia and South Africa, where patents have issued already."  

Endometriosis is a serious medical condition where endometrial stroma and glands that are normally present in the uterine cavity are found in other parts of the body.  Endometriosis lesions can be found anywhere in the pelvic cavity.  The most common symptom of endometriosis is pelvic pain, which often correlates to the menstrual cycle, but a woman with endometriosis may also experience pain that doesn't correlate to her cycle.  For many women, the pain of endometriosis is so severe and debilitating that it significantly impacts their daily lives.

It is estimated that seven to 10 percent of all women are affected by endometriosis, including 70 to 87 percent of women with chronic pelvic pain and 30 to 40 percent of all infertile women.  Chronic pelvic pain, dysmenorrhea (painful periods) and dyspareunia (painful intercourse) are common symptoms of endometriosis.  There are several medical treatment options, including danazol, GnRH agonists and progestins, each of which have limitations associated with patient response, tolerability, side-effect profile and duration of treatment.

About MPI-676

MPI-676 is based on anastrozole, an aromatase inhibitor (AI) with well-established, multi-year chronic safety and tolerability data. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.  In endometriosis, AIs act primarily by inhibiting local estradiol production inside the endometrial lesions.  

AIs are currently used for the chronic treatment of estrogen-dependent tumors in postmenopausal women and are being investigated in a variety of women's health conditions. Meditrina holds the exclusive worldwide rights to AstraZeneca's patents and patent applications covering the use of AIs in gynecologic indications.

About Meditrina Pharmaceuticals, Inc.

Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs.  By identifying, leveraging and repurposing marketed products and product candidates at advanced stages of development, Meditrina's novel therapies have the potential to significantly alter the way these women's health conditions are treated.  For more information about Meditrina Pharmaceuticals, please visit

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  For more information please visit:

Meditrina Pharmaceuticals, Inc. Forward-Looking Statement Disclaimer

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
7. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Post Your Comments:
(Date:11/24/2015)... , November 25, 2015 ... due to repeated failure of IVF cycles. After failure ... was totally dejected and had lost all hopes that she would be able ... Indian miracle child conceived after failure of over 15 ... abroad (UK) before they decided to take one last attempt with ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
(Date:11/24/2015)... /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") ... the first patient has been enrolled in ESSA,s Phase ... metastatic castration-resistant prostate cancer ("mCRPC"). the ... the United States and Canada.  ... trial, ESSA intends to demonstrate the safety, tolerability, maximum ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 10, ... States District Court of Connecticut on behalf of a home health care worker who ... current or former home health care workers employed by Humana, Inc., Humana at Home, ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
(Date:11/25/2015)... ... , ... SCOTTSDALE, AZ) - Today, Dr. Todd C. ... and non-surgical treatments, announced the expansion of his private practice capabilities with the ... Highly trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Today, ... on our nation’s roadways has dropped below 10,000 for the first time since 2011. ... in 2013. , According to data released by the National Highway Traffic Safety Administration ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
Breaking Medicine News(10 mins):